(相关资料图)

Photo/VCG

BeiGene"s star product, Brukinsa has encountered trouble. According to reports, AbbVie Inc. claims that BeiGene"s cancer drgu Brukinsa infringes on its patent and will file a lawsuit in a US district court.

On the afternoon of June 15th, a BeiGene spokesperson told National Business Daily (NBD) on WeChat that they are aware of the situation and will respond to the complaint at the appropriate time and actively defend themselves.

Data shows that BeiGene achieved revenue of 9.566 billion yuan in 2022, a year-on-year increase of 26.1%. Among them, the global sales of Brukinsa reached 3.829 billion yuan, with sales in the United States reaching 2.644 billion yuan. Currently, Brukinsa"s revenue in the US market accounts for nearly 70% of BeiGene"s global sales.

In the afternoon, BeiGene"s stock price in the Shanghai Stock Exchange fell against the trend, closing down 14.06% and hitting a new low for the year.